Safety of the Immunosuppressing Disease-Modifying Therapies in Multiple Sclerosis
The article presents the authors’ own data and the literature data concerning studies of pathogenesis and treatment of multiple sclerosis (MS). We emphasize the need of complex assessment of patients with MS, which allows to define importance of the involvement of brain cortex and subcortical structures in mechanisms of the disease development, as well as promotes the improvement of diagnostic and therapeutic approaches in MS. Intensive studies of MS pathogenesis led to the identification of new therapeutic targets and the emergence of new effective medications that modify pathological autoimmune processes. However, in some cases selective immunosuppression results not only in the therapeutic effect, but also in the induction of viral and bacterial infections and uncontrollable cell proliferation. The relevance of careful analysis of the side effects arising on pathogenic therapy, including the use of selective drugs, and the need for balanced assessment of the whole spectrum of therapeutic effects of immunosuppressing disease-modifying therapies in MS disease is noted.